Drug Notebook

FDA Alerts

    Cardiotoxicity
  • Risk of cardiotoxicity (e.g., ventricular dysfunction, CHF).
  • Evaluate left ventricular function prior to and during therapy.
  • Discontinuance of trastuzumab should be strongly considered in patients who develop a clinically important decrease in left ventricular function.
    Anthracyclines and Cyclophosphamide
  • Increased frequency and severity of cardiac toxicity when used in combination with an anthracycline and cyclophosphamide.
    Hypersensitivity, Infusion, and Pulmonary Reactions
  • Risk of severe (rarely fatal) hypersensitivity reactions, (e.g., anaphylaxis), infusion reactions, or severe pulmonary effects.
  • Onset of symptoms generally occurs during or within 24 hours of initiation of the infusion.
  • Interrupt infusion in patients who develop dyspnea or clinically important hypotension.
  • Patients should be monitored until signs and symptoms of these effects completely resolve.
  • Discontinuance of trastuzumab should be strongly considered in patients who develop anaphylaxis, angioedema, or acute respiratory distress syndrome (ARDS).

Drug Info Tools
Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
trastuzumab
Page: 1 2 3 Next >
(tras TOO zoo mab)

What is the most important information I should know about trastuzumab?

Do not use this medication without telling your doctor if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment.

Before receiving trastuzumab, tell your doctor if you have heart disease, congestive heart failure, a history of heart attack, or any allergies or breathing problems. You may not be able to receive trastuzumab, or you may need a dosage adjustment or special tests during treatment.

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.

What is trastuzumab?

Trastuzumab is a cancer medication. It interferes with the growth of cancer cells and slows their growth and spread in your body.

Trastuzumab is used to treat breast cancer that has progressed after treatment with other chemotherapy.

Trastuzumab may also be used for purposes other than those listed in this medication guide.

What should I discuss with my health care provider before receiving trastuzumab?

Before using trastuzumab, tell your doctor if you are allergic to any drugs, or if you have:

  • heart disease;

  • congestive heart failure;

  • a history of heart attack; or

  • any allergies or breathing problems.

If you have any of these conditions, you may not be able to receive trastuzumab, or you may need a dosage adjustment or special tests during treatment.

FDA pregnancy category D. Trastuzumab can cause harm to an unborn baby. Do not use trastuzumab without telling your doctor if you are pregnant. Use effective birth control, and tell your doctor if you become pregnant during treatment.

If you are pregnant, your name may need to be listed on a Cancer and Childbirth registry when you start using this medication.

It is not known whether trastuzumab passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Page: 1 2 3 Next >
Advertisement
Back to Top